Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T21:32:24.731Z.
Calculation as of: 2026-10-06T21:32:24.731Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e5bf89a371f0468543faa328a941ad2f1c46577ddea7987f626d68fdce73ba7d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$8.33M
Price/FCF Ratio
N/A
TTM Avg
9.96
3Y Avg
9.96
5Y Avg
9.96
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HeartSciences Inc. (HSCS) | $8.14M | N/A | N/A | N/A | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.05M | N/A | N/A | N/A | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $8.04M | N/A | N/A | N/A | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.33M | N/A | 9.96 | 9.96 | 9.96 |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | N/A | N/A | N/A | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.87M | N/A | N/A | N/A | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | N/A | N/A | N/A | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.67M | N/A | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.64M | N/A | N/A | N/A | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $8.82M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
